Medical Service (612/111), Veterans Affairs Northern California Health Care System (VANCHCS), Martinez, California, USA.
Department of Medicine, UC Davis School of Medicine, Sacramento, California, USA.
Metab Syndr Relat Disord. 2021 Aug;19(6):317-324. doi: 10.1089/met.2020.0070. Epub 2021 Mar 3.
Although the prevalence of pancreatic cancer is increasing, treatment strategies remain limited, and success is rare. A growing body of evidence links pancreatic cancer to pre-existing metabolic disorders, including, but not limited to, type 2 diabetes mellitus and obesity. An infrequently described finding, fatty pancreas, initially described in the context of obesity in the early 20th century, appears to be at the crossroads of type 2 diabetes and obesity on the one hand, and the development of pancreatic cancer on the other. Similarly, other conditions of the pancreas, such as intrapancreatic mucinous neoplasms, also seem to be related to diabetes while increasing the subsequent risk of pancreatic cancer. In this review, the author explores the diagnostic criteria for, and prevalence of, fatty pancreas and the potential link to other pancreatic conditions, including pancreatic cancer. Diagnostic limitations, and areas of controversy are also addressed, as are potential therapeutic approaches to fatty pancreas intended to reduce the subsequent risk of pancreatic cancer.
尽管胰腺癌的发病率正在上升，但治疗策略仍然有限，成功的案例很少。越来越多的证据将胰腺癌与先前存在的代谢紊乱联系起来，包括但不限于 2 型糖尿病和肥胖症。脂肪胰腺是一种不常被描述的发现，最初在 20 世纪早期肥胖的背景下被描述，它似乎处于 2 型糖尿病和肥胖症一方面，以及胰腺癌发展的另一方面的交叉点。同样，胰腺的其他状况，如胰内黏液性肿瘤，似乎也与糖尿病有关，同时增加了随后患胰腺癌的风险。在这篇综述中，作者探讨了脂肪胰腺的诊断标准和流行率，以及与其他胰腺疾病（包括胰腺癌）的潜在联系。还讨论了诊断的局限性和争议领域，以及旨在降低随后胰腺癌风险的脂肪胰腺的潜在治疗方法。
